Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of olaratumab plus gemcitabine + docetaxel in advanced soft tissue sarcoma
2015-001316-34Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaratumab in soft tissue sarcoma (STS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival. Started Nov 2015; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2015-001316-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001316-34.